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Introduction {#sec1}
============

Temporal transcriptional control of gene expression is often achieved through the dynamic interactions of activator and repressor proteins with promoters. One of the most common ways of switching between these two modes is through competition for promoter occupancy by mutually exclusive binding to the same DNA site (reviewed in [@bib31]). However, this mechanism is only generally applicable to proteins that share overlapping DNA binding specificities and are usually from the same transcription factor family. More elaborate mechanisms must be employed if no overlap in DNA-binding site is possible, although little is known about such mechanisms.

Cell cycle-dependent gene expression provides an excellent model to study temporal transcriptional control mechanisms. Indeed, among multiple regulatory mechanisms of cell-cycle progression, one of the most important control points is at the transcriptional level and leads to the expression of key regulators in a cyclical manner ([@bib28]; reviewed in [@bib35]). Peaks of gene expression can be identified at various points in the cell cycle, but two important control points in *Saccharomyces cerevisiae* are at the G2/M phase and M/G1 phase transitions (reviewed in [@bib35]). The MADS box transcription factor Mcm1p plays an important role in the transcriptional regulation of genes expressed at both of these control points. At G2/M phase, Mcm1p controls the expression of a group of genes known as the *CLB2* cluster, which contains targets such as *CLB2*, *CDC20*, and *SPO12* ([@bib1]). Mcm1p forms a complex on *CLB2* gene cluster promoters with the forkhead transcription factor Fkh2p ([@bib14; @bib15; @bib23; @bib37]; reviewed in [@bib3]) and the coactivator Ndd1p ([@bib14; @bib20]). This complex is regulated by cell cycle-dependent kinases that cooperate to give maximal activation through sequential phosphorylation of Fkh2p and Ndd1p ([@bib7; @bib6; @bib26; @bib24]). Mcm1p also forms higher-order complexes on early cell cycle box (ECB) elements at promoters of genes expressed at the M/G1 phase transition such as *CLN3* and *MCM3* ([@bib21]). However, in contrast to the *CLB2* gene cluster, no positively acting partner protein(s) has yet been found that cooperates with Mcm1p to regulate these M/G1 phase genes. More recently, the closely related homeodomain repressor proteins Yox1p and Yhp1p were shown to play a repressive role at ECB-containing promoters ([@bib25]). Yox1p and Yhp1p interact directly with Mcm1p as well as forming protein-DNA contacts with a binding site adjacent to the Mcm1p recognition element in the ECB ([@bib25]). Moreover, similar Yox1p-binding sites can be found in the promoters of a subset of genes from the *CLB2* gene cluster such as *CDC20* and *SPO12*. Importantly, loss of Yox1p and Yhp1p alters the precise timing of the expression of these genes in the cell cycle, but not of other genes in the *CLB2* gene cluster such as *CLB2* itself ([@bib25]). This suggests that Yox1p also plays a key role in controlling the timing of expression of a subset of *CLB2* cluster genes, restricting their expression to a later time point in the cell cycle than other genes of the *CLB2* gene cluster. It is unclear whether similar control mechanisms operate in mammalian cells, but homeodomain proteins are known to interact with SRF, the mammalian homolog of Mcm1p ([@bib9; @bib4]). Moreover, forkhead proteins play an important role in cell-cycle control in mammals (reviewed in [@bib17; @bib16]), and at least two of these, Foxo3 and FOXK1, can directly affect SRF function ([@bib19; @bib8]). Thus, it is important to understand the relationships and functions of the interactions between forkhead, homeodomain, and MADS box proteins.

Despite the importance of Yox1p in the regulation of cell cycle-dependent gene expression, little is known about how it represses Mcm1p transcription factor complexes. With regard to the Mcm1p-Fkh2p complex, a simple competition model between Yox1p and the activator Fkh2p for a common DNA-binding site seemed unlikely, as the Yox1p and Fkh2p DNA-binding sites are positioned on the opposite sides of the Mcm1p-binding motif (e.g., see [Figure 1](#fig1){ref-type="fig"}A). Thus, to begin to understand the repressive process, we investigated the molecular mechanisms through which Yox1p interacts with Mcm1p. Unexpectedly, Yox1p binding to Mcm1p is mutually exclusive with Fkh2p binding despite the spatial separation of their DNA recognition elements. Our data therefore reveal an atypical mode of repression that involves competition between an activator protein and a repressor protein for interaction with a common "combinatorial partner" rather than for a common DNA recognition element.

Results {#sec2}
=======

Mapping the Determinants for Formation of the Yox1p-Mcm1p Ternary DNA-Bound Complex {#sec2.1}
-----------------------------------------------------------------------------------

Yox1p negatively regulates a number of genes whose expression peaks transiently during the M phase of the cell cycle, including *MCM3*, which is usually expressed at the M/G1 border ([@bib25]). However, Yox1p also appears to be important for repressing genes that are expressed earlier in M phase such as *SPO12*. The *SPO12* promoter contains a putative Yox1p-binding site juxtaposed to a Mcm1p-binding site ([Figure 1](#fig1){ref-type="fig"}A). Hence, to establish whether a Yox1p-Mcm1p complex forms on alternative promoters in addition to *MCM3* and, if so, whether Mcm1p and Yox1p are sufficient for complex formation, we carried out an immobilized template-binding assay using a recombinant version of Mcm1p (Mcm1p(1--98)), in vitro-translated full-length Yox1p, and a fragment spanning the putative Yox1p-binding element in the *SPO12* promoter. Mcm1p(1--98) spans the DNA-binding domain and is sufficient for cell viability ([@bib5]). Although binding of Yox1p to the *SPO12* promoter was readily detectable in the presence of Mcm1p, little binding of Yox1p was seen when Mcm1p was not added, or the DNA was omitted from the reaction ([Figure 1](#fig1){ref-type="fig"}B).

To map the region(s) of Yox1p required for complex formation with DNA-bound Mcm1p, we first carried out gel retardation analysis with a short region of Yox1p centered on the DNA-binding homeodomain region ([Figure 1](#fig1){ref-type="fig"}C). Yox1p(151--274) bound weakly to the *SPO12* promoter in the absence of Mcm1p, but cooperative strong binding was detected upon addition of Mcm1p ([Figure 1](#fig1){ref-type="fig"}D, compare lanes 3 and 5). The identity of the Yox1p-containing complexes was confirmed by the partial supershifts/loss of binding of Flag-tagged Yox1p, which is seen upon inclusion of an anti-Flag antibody ([Figure 1](#fig1){ref-type="fig"}D, lanes 5 and 6). In contrast, addition of Fkh2p to the binding reaction did not promote the formation of Yox1p DNA-bound complexes ([Figure 1](#fig1){ref-type="fig"}E).

Further deletion analysis of Yox1p demonstrated that the region preceding the homeodomain (amino acids 151--175) was critical for the formation of Mcm1p-dependent ternary DNA-bound complexes ([Figure 1](#fig1){ref-type="fig"}F, compare lanes 2 and 4 with lanes 6 and 8). Importantly, deletion of this region of Yox1p did not affect its intrinsic DNA binding properties, as both Yox1p(151--274) and a protein lacking amino acids 151--175 (Yox1p(176--274)) bound to the *SPO12* promoter with equivalent affinities when titrated at higher protein concentrations ([Figure S1](#app2){ref-type="sec"}B available online). Thus, amino acids in the region immediately flanking the N terminus of the homeodomain of Yox1p play a critical role in promoting ternary complex formation with Mcm1p and the *SPO12* promoter.

Several other yeast transcription factors use sequences in addition to their DNA-binding domains to enhance the formation of complexes with Mcm1p through direct protein-protein interactions ([@bib2; @bib22; @bib30]). Thus, one likely role for Yox1p sequences that are located outside of the homeodomain and are involved in ternary complex formation is binding to Mcm1p. This was tested by in vitro pull-down assays using recombinant MBP-Mcm1p fusion proteins and either in vitro-translated or recombinant forms of Yox1p. Both full-length Yox1p and the truncated Yox1p(151--274) could form complexes with Mcm1p ([Figure S1](#app2){ref-type="sec"}C). However, further truncation of Yox1p to remove amino acids 151--175, Yox1p(176--274), resulted in a substantial loss of interaction with Mcm1p ([Figure 1](#fig1){ref-type="fig"}G). Importantly, the inclusion of ethidium bromide in the binding reaction did not stop this interaction, demonstrating that the binding was not mediated through interactions with contaminating nonspecific DNA ([Figure S1](#app2){ref-type="sec"}D). Hence, amino acids located in the immediate N-terminal flanking region of the homeodomain of Yox1p are important for protein-protein interactions with Mcm1p.

A putative Yox1p-binding site flanks the Mcm1p-binding site in the *SPO12* promoter ([Figure 1](#fig1){ref-type="fig"}A; [@bib25]). To probe the importance of this site for Yox1p binding, a mutant form of the *SPO12* promoter was analyzed that contained a disrupted Yox1p-binding site ([Figure 2](#fig2){ref-type="fig"}A). Whereas Yox1p-Mcm1p complexes could readily be detected on the wild-type *SPO12* promoter, no Yox1p-Mcm1p complexes were detectable when the putative Yox1p-binding site had been mutated ([Figure 2](#fig2){ref-type="fig"}B, compare lanes 3 and 8). In contrast, Mcm1p binding was unaffected and Fkh2p-Mcm1p complexes could form with equal efficiency on either the wild-type or the mutant *SPO12* promoter ([Figure 2](#fig2){ref-type="fig"}B, compare lanes 1 and 5 with lanes 6 and 10).

To further assess the DNA-binding site requirements for Yox1p recruitment to DNA, we moved the Yox1p site away from the Mcm1p site by either two or five nucleotides while keeping the sequence of the Yox1p-binding motif intact. The formation of Yox1p-Mcm1p complexes decreased upon insertion of two nucleotides between the Yox1p- and Mcm1p-binding sites and was further diminished upon insertion of five nucleotides ([Figure 2](#fig2){ref-type="fig"}C).

These data indicate that Yox1p-DNA interactions are essential for the formation of DNA-bound Yox1p-Mcm1p complexes and that the correct spacing of the two binding sites is critically important for efficient complex formation.

Identification of Amino Acids Critical for Yox1p Interaction with Mcm1p {#sec2.2}
-----------------------------------------------------------------------

Other proteins that interact with Mcm1p to form ternary DNA-bound complexes such as MATα2 ([@bib22; @bib30]) and Fkh2p ([@bib2]) use short peptide motifs for direct binding to Mcm1p in which aromatic residues are the major interaction determinants. There are three aromatic residues in the region between amino acids 151 and 174 in Yox1p ([Figure 3](#fig3){ref-type="fig"}A), and hence we tested their importance for complex formation with Mcm1p. MBP pull-down assays with Yox1p proteins mutated at either F153, F155, or F163 showed much-reduced interaction with Mcm1p, indicating an important role for these individual Phe residues ([Figure 3](#fig3){ref-type="fig"}B). Furthermore, the ability of these mutant versions of Yox1p to form complexes with Mcm1p on the *SPO12* promoter was severely reduced ([Figure 3](#fig3){ref-type="fig"}C, lanes 7--10), although their autonomous DNA binding ability was unaffected ([Figure 3](#fig3){ref-type="fig"}C, lanes 2--5). Moreover, titration experiments with recombinant Yox1p proteins confirmed the reduced ternary complex forming ability of the Yox1p mutant proteins on an alternative binding site derived from the *MCM3* promoter ([Figure S2](#app2){ref-type="sec"}B).

Collectively, these results demonstrate that aromatic residues in the region preceding the homeodomain of Yox1p play critical roles in complex formation with Mcm1p.

The Determinants for Phox1-SRF and Yox1p-Mcm1p Complex Formation Differ {#sec2.3}
-----------------------------------------------------------------------

Yox1p was originally identified based on the premise that it was the most related yeast protein to human Phox1, which interacts with the MADS box protein SRF ([@bib25]). Complex formation between Phox1 and SRF is thought to be driven by the homeodomain ([@bib9]), and single amino acid mutations, such as E114H, were shown to disrupt functional interactions between Phox1 and SRF on reporter genes ([@bib29]). However, Phox1 shows little homology with Yox1p in the region immediately N terminal to the homeodomain, which was mapped as important for Yox1p binding to Mcm1p. To probe whether the homeodomain might also be involved in the Yox1p-Mcm1p interaction, we introduced an amino acid substitution (E196H) into the equivalent position in the homeodomain of Yox1p. However, this mutant protein was still able to efficiently form complexes with Mcm1p both in solution ([Figure S2](#app2){ref-type="sec"}E) and on DNA ([Figure S2](#app2){ref-type="sec"}F). In contrast, the mutant protein Yox1p(N226Q), which was predicted to be unable to bind DNA based on similarities to Phox1 ([@bib9]), was unable to form ternary complexes with Mcm1p on DNA ([Figure S3](#app2){ref-type="sec"}D), although it could still bind to Mcm1p in solution ([Figure S2](#app2){ref-type="sec"}D).

Thus, the mechanisms used by Phox1 and Yox1p to bind to MADS box proteins differ substantially, with Phox1 primarily using the homeodomain whereas Yox1p uses a unique region preceding the homeodomain.

F155 Plays a Critical Role in Yox1p Function In Vivo {#sec2.4}
----------------------------------------------------

To establish whether the interactions that we detect in vitro are important for the in vivo function of Yox1p, we examined the effect of introducing wild-type (WT) Yox1p and Yox1p(F155A), expressed under the control of its own promoter, from the YCplac22 vector into a *yox1*Δ*yhp1*Δ double-mutant strain. The expression levels of both forms of Yox1p were identical ([Figure 4](#fig4){ref-type="fig"}A), and the overall cell-cycle profiles were similar for both strains when released from α factor arrest ([Figure S3](#app2){ref-type="sec"}A). However, differences were detected in the levels of expression of several potential Yox1p-Mcm1p-regulated genes. The expression of the G2-M phase-expressed genes *SPO12* and *CDC20* and the M-G1 phase-expressed gene *MCM3* are severely perturbed, with both earlier onset (28 versus 42 min for *SPO12*) and higher levels of expression being detected in the strain expressing Yox1p(F155A) ([Figure 4](#fig4){ref-type="fig"}B). These genes all contain potential Yox1p-binding sites in their promoters. In contrast, the expression of the late G1 phase-expressed gene *CLN2* and the G2-M phase-expressed gene *CLB2*, which do not contain Yox1p-binding sites in their promoters, were not derepressed and displayed more similar timing of cyclical expression in cells expressing Yox1p(F155A) compared with those expressing wild-type Yox1p ([Figure 4](#fig4){ref-type="fig"}B). The premature and higher than normal expression of a subset of G2-M and M-G1 phase-expressed genes in the presence of Yox1p(F155A) is similar to the effects seen when both *YOX1* and *YHP1* are deleted ([Figure S3](#app2){ref-type="sec"}B; [@bib25]). This effect is consistent with a loss-of-function mutation of Yox1p, although additional residual activities of Yox1p(F155A) appear likely due to the extended activation in comparison to complete loss of Yox1p.

To establish whether the effects of the F155A mutation on *SPO12* and *MCM3* gene expression were due to lack of promoter binding by Yox1p(F155A), ChIP analysis was performed. As expected, cyclical binding of wild-type Yox1p could be detected on the *SPO12* and *MCM3* promoters, with the timing of reduction of Yox1p binding in G2-M phases corresponding to the timing of increased expression of *SPO12* and *MCM3* (compare [Figures 4](#fig4){ref-type="fig"}B and 4C). However, promoter binding was largely abolished in strains expressing Yox1p(F155A) ([Figure 4](#fig4){ref-type="fig"}C).

Collectively, these data therefore establish that mutation of the Mcm1p-interacting region of Yox1p reduces its recruitment to promoters and thereby compromises temporal Yox1p-mediated repression of promoter activity.

Yox1p and Fkh2p Binding to Mcm1p Involves a Common Binding Pocket {#sec2.5}
-----------------------------------------------------------------

Mcm1p contains a hydrophobic pocket found on the surface of the MADS DNA-binding domain ([@bib30]), and mutation of this pocket on Mcm1p by the introduction of a V69E mutation disrupts interactions with Fkh2p ([@bib2]). To establish whether the same pocket on Mcm1p is involved in binding Yox1p, we first tested protein-protein interactions between Yox1p and the V69E mutant form of Mcm1p. In comparison to wild-type Mcm1p(WT), Mcm1p(V69E) exhibited reduced interactions with both Yox1p and Fkh2p ([Figure S4](#app2){ref-type="sec"}A). Furthermore, the formation of DNA-bound ternary complexes containing Mcm1p and either Yox1p or Fkh2p was severely attenuated in the presence of Mcm1p(V69E) ([Figure S4](#app2){ref-type="sec"}B). However, interactions between Yox1p and the surface of the MADS DNA-binding domain are likely to be subtly different than those mediated by Fkh2p, as only Fkh2p can form detectable interactions with the mammalian protein SRF, albeit weakly ([Figure S4](#app2){ref-type="sec"}C).

Together, these results demonstrate that both Yox1p and Fkh2p bind to a region centered on a hydrophobic pocket on the surface of the MADS box DNA-binding domain of Mcm1p.

Mutually Exclusive Binding of Yox1p and Fkh2p to Mcm1p {#sec2.6}
------------------------------------------------------

As both Yox1p and Fkh2p bind to a region centered on the same hydrophobic pocket on Mcm1p, this raised the possibility that they bind in a mutually exclusive manner to Mcm1p. We therefore tested this by titrating increasing amounts of Yox1p into binding reactions containing Mcm1p and Fkh2p proteins. Indeed, increasing concentrations of Yox1p caused a loss of Fkh2p-Mcm1p ternary complex formation, involving both full-length Fkh2p(1--862) and the truncated Fkh2p(1--458) version, with concomitant formation of an Mcm1p-Yox1p complex ([Figures 5](#fig5){ref-type="fig"}B, [S4](#app2){ref-type="sec"}E, and S4F). Similarly, increasing amounts of full-length Fkh2p could outcompete Yox1p binding to Mcm1p on the *SPO12* promoter in a dose-dependent manner ([Figure 5](#fig5){ref-type="fig"}C), and Fkh2p(1--458) could block Yox1p binding ([Figure S4](#app2){ref-type="sec"}F, lanes 8 and 9). This finding is surprising as Mcm1p is dimeric, and in theory, both Fkh2p and Yox1p would be expected to bind simultaneously; however, there was no sign of a higher-order complex containing Fkh2p, Yox1p, and Mcm1p, even when recombinant proteins were used to eliminate the nonspecific bands on the gel ([Figure S4](#app2){ref-type="sec"}F). To rule out potential effects transmitted through the DNA, we performed gel retardation experiments in the presence of the isolated forkhead DNA-binding domain of Fkh2p (Fkh2p(325--458)) ([Figure S4](#app2){ref-type="sec"}F). This truncated protein is unable to cooperatively form complexes with Mcm1p ([@bib2]) but at high concentrations can bind to the *SPO12* promoter. In contrast to the results seen with longer forms of Fkh2p, Fkh2p(325--458) did not compete with Yox1p for Mcm1p binding but instead was able to form a higher-order complex containing Fkh2p, Yox1p, and Mcm1p ([Figure 5](#fig5){ref-type="fig"}D, lanes 3--5). Thus, interaction of Fkh2p with Mcm1p appears essential to establish competitive binding.

To further establish a role for protein-protein interactions in establishing the competitive binding mechanism, we analyzed the effects of mutant proteins and DNA-binding elements on the competition phenomenon. Hydrophobic residues in both Fkh2p ([@bib2]) and Yox1p play major roles in interaction with Mcm1p. We therefore tested Yox1p(F155A) for its ability to displace Fkh2p from Fkh2p-Mcm1p complexes. In comparison to wild-type Yox1p, Yox1p(F155A) showed much-reduced ability to compete with Fkh2p for Mcm1p binding ([Figure 6](#fig6){ref-type="fig"}A, lanes 1--7), even though its intrinsic DNA binding ability is unperturbed ([Figure 3](#fig3){ref-type="fig"}C). These results demonstrate the importance of protein-protein interactions in the displacement mechanism. Moreover, wild-type Yox1p was unable to compete efficiently with Fkh2p for complex formation with Mcm1p when the Yox1p-binding site on the *SPO12* promoter was mutated ([Figure 6](#fig6){ref-type="fig"}A, lanes 8--11), demonstrating that DNA binding, in addition to protein-protein interactions, is required for effective competition. Furthermore, when the spacing of the Yox1p- and Mcm1p-binding sites is increased, competition with Fkh2p for binding to Mcm1p is diminished ([Figure S5](#app2){ref-type="sec"}). This point was further underlined by the observation that a DNA-binding incompetent form of Yox1p (Yox1p(N226Q)) was unable to compete with Fkh2p for binding to Mcm1p on the wild-type *SPO12* promoter fragment ([Figure 6](#fig6){ref-type="fig"}B).

Together, these results demonstrate that the formation of DNA-bound complexes between Mcm1p and either Yox1p or Fkh2p is a mutually exclusive event. Moreover, we establish that both protein-protein and protein-DNA interactions by Yox1p are essential to enable the protein to compete with Fkh2p for complex formation with Mcm1p.

Yox1p Acts to Limit Promoter Occupancy by Fkh2p In Vivo {#sec2.7}
-------------------------------------------------------

As Fkh2p is an activator protein that cyclically associates with its target promoters ([@bib34]) and Yox1p is a repressor protein that displays cyclical stability and association with target promoters ([@bib25]), it was possible that competition between Yox1p and Fkh2p for interaction with Mcm1p could explain how Yox1p can repress the expression of a subset of Fkh2p target genes that contain Yox1p-binding sites. We therefore tested this hypothesis by first examining the occupancy of wild-type and mutant versions of the promoter of the Yox1p/Fkh2p target gene *SPO12* in vivo. To rule out indirect effects of potentially perturbing the cell cycle by affecting endogenous *SPO12* expression, we integrated a plasmid containing a fusion of the *SPO12* promoter linked to the *E. coli LacZ* gene. Strains harboring the wild-type promoter and a mutant version with a disrupted Yox1p-binding site ([Figure 2](#fig2){ref-type="fig"}A) were created, and the effect on promoter activity was determined by measuring β-galactosidase activity. As expected, the activity of the mutant promoter was increased through loss of binding of the Yox1p repressor ([Figure 7](#fig7){ref-type="fig"}A). Next, we performed ChIP analysis to determine promoter occupancy by Fkh2p and Ndd1p. As a control, we determined the occupancy of the endogenous *CLB2* promoter, which was unchanged irrespective of the status of the *SPO12* promoter fusion ([Figures 7](#fig7){ref-type="fig"}B and 7C). In contrast, upon mutation of the Yox1p site, occupancy by either Fkh2p ([Figure 7](#fig7){ref-type="fig"}B) or Ndd1p ([Figure 7](#fig7){ref-type="fig"}C) on the *SPO12* promoter fusion rose substantially.

Next, we examined the effect of overexpression of either wild-type Yox1p or Yox1p(F155A) that is defective in Mcm1p binding and Fkh2p displacement activity in vitro. In this case, we used Ndd1p as a readout to indicate that correctly formed Fkh2p-Mcm1p complexes were assembled on the promoter ([@bib14]). Induction of wild-type Yox1p resulted in a decrease in Ndd1p occupancy on the endogenous *SPO12* promoter, which contains a juxtaposed Yox1p-binding site ([Figure 7](#fig7){ref-type="fig"}D). However, overexpression of Yox1p(F155A) was unable to efficiently displace Ndd1p binding from the *SPO12* promoter. Importantly, both wild-type and mutant forms of Yox1p were expressed to similar levels ([Figure S6](#app2){ref-type="sec"}).

As a final test of our model, we performed re-ChIP analysis to examine whether co-occupancy of the *SPO12* promoter by Fkh2p and Yox1p could be detected. However, whereas Mcm1p binding to the *SPO12* promoter could be detected in both Fkh2p- and Yox1p-precipitated material, little binding of Fkh2p was detectable when Yox1p was used in the first ChIP, and conversely, little binding of Yox1p was detectable when Fkh2p was used in the first ChIP ([Figure 7](#fig7){ref-type="fig"}E). As expected, only Fkh2p-Mcm1p or Yox1p-Mcm1p co-occupancy was detected at the *CLB2* and *MCM3* promoters, respectively ([Figure 7](#fig7){ref-type="fig"}E). Thus, the absence of detectable complexes containing both Fkh2p and Yox1p on the *SPO12* promoter in vivo is fully consistent with our model in which Yox1p and Fkh2p compete for interaction with promoter-bound Mcm1p.

Discussion {#sec3}
==========

Transcriptional regulation during the eukaryotic cell cycle is complex. Recent studies in *S. cerevisiae* indicate that, rather than two major waves of gene expression at G1/S and G2/M phases, there are many overlapping waves of expression with subtly different timing mechanisms, each with their associated transcriptional regulatory circuitry. Although a limited number of regulators have been identified, it is becoming increasingly apparent that these can be combined in different ways to provide unique control opportunities to individual or subsets of promoters, determining precise timings of cell cycle-dependent gene expression ([@bib12; @bib13; @bib18]). Here, we have uncovered an atypical mechanism of antagonism between transcriptional activators and repressors during M phase of the cell cycle. Mcm1p acts as a common platform for recruitment of the homeodomain repressor protein Yox1p and the forkhead transcription activator protein Fkh2p. These interactions with Mcm1p are mutually exclusive, and hence, the timing of recruitment of these two regulators to promoters during the cell cycle determines the transcriptional status of cyclically regulated target genes.

Interactions between Yox1p and Mcm1p are driven via a combination of protein-DNA interactions involving the homeodomain of Yox1p and through direct protein-protein interactions with the MADS box DNA-binding domain of Mcm1p. Though we have only tested the DNA-binding domain of Mcm1p in vitro, it is likely that the interactions are relevant to full-length Mcm1p as we validate our results in vivo wherein full-length Mcm1p is present. Several aromatic residues that are clustered on a short peptide in the flanking region located N terminal to the homeodomain of Yox1p were found to be important for these interactions. Many other yeast and mammalian transcription factors use short peptides that are distinct from their DNA-binding domains to bind to MADS box proteins ([@bib22; @bib30; @bib10; @bib27]). A common feature is the use of aromatic residues to drive the protein-protein interactions with the MADS box partner proteins. Indeed, the structures of the MATα2-Mcm1p and SAP-1-SRF complexes both reveal that hydrophobic residues insert into a common hydrophobic pocket found on the surface of the MADS DNA-binding domain ([@bib30; @bib10]). Furthermore, molecular studies have implicated the same hydrophobic pocket as a major determinant of Fkh2p-Mcm1p interactions, most likely through insertion of an aromatic residue from Fkh2p, as there are three important aromatic residues in Fkh2p required for interaction with Mcm1p ([@bib2]). In mammalian systems, the coactivator MAL also uses aromatic residues to interact with the hydrophobic pocket on SRF ([@bib36]). Thus, a common mode of interaction between MADS box proteins and their interaction partners has been adopted by a heterologous array of binding partners. However, despite these similarities, there are key differences in how some proteins interact with MADS box proteins. This is exemplified by the closest human homologs of Fkh2p and Yox1p, FOXK1 and Phox1, respectively. FOXK1 interactions with SRF are driven by the forkhead DNA-binding domain rather than a flanking peptide ([@bib8]), and interactions between Phox1 and SRF appear to be directed by the homeodomain ([@bib9]), although direct biochemical proof of the latter is lacking. Similarly, the homeodomain of Nkx-2.5 is sufficient for binding to SRF ([@bib4]). However, it is striking that, in yeast, flanking DNA-binding sites for Fkh2p and Yox1p can be found in close juxtaposition to Mcm1p DNA-binding sites, whereas in mammals, there does not appear to be such combinatorial sites. This suggests that the role of the DNA-binding domain of MADS box-interacting proteins has been subverted through evolution from primarily mediating protein-DNA contacts in yeast to providing protein-protein interactions in higher organisms.

The direct competition for Mcm1p binding by Yox1p and Fkh2p was unexpected due to the clear separation of their DNA-binding sites on opposite sides of the Mcm1p DNA-binding site ([Figure 7](#fig7){ref-type="fig"}F). However, each protein contacts a region centered on the same binding pocket of Mcm1p, and as interaction with Mcm1p is essential for the recruitment of both Fkh2p ([@bib2; @bib11]) and Yox1p, only one protein can be recruited at a time. Mcm1p is a dimer and, as such, can theoretically present two identical surfaces that could accommodate two interacting proteins. However, as this clearly does not occur, it suggests that these proteins lack the flexibility to interact with both surfaces of Mcm1p, and that the structure of the DNA-bound complex adds constraints, which means that only one of these proteins is allowed to bind to one (the same) surface of Mcm1p at any given time. Alternatively, it is possible that protein binding to Mcm1p straddles both sides of Mcm1p, preventing proper access to the second binding surface. Indeed, it is possible that Fkh2p binds as a dimer with only one subunit contacting DNA, as Fkh2p dimerization has been reported previously ([@bib11]). Of interest, a similar scenario has been observed in mammalian systems in which the activator proteins MAL and Elk-1 compete for binding to the same surface of the dimeric MADS box protein SRF, despite both apparently functioning as monomers ([@bib36]). Further structural studies are needed to establish the exact molecular architecture of these complexes.

It was previously suggested that Yox1p might function to displace the coactivator protein Ndd1p ([@bib25]). Here, we show that this does occur but through an indirect mechanism by displacing Fkh2p and, hence, concomitant loss of Ndd1p binding ([Figures 7](#fig7){ref-type="fig"}B--7F). At the transcriptional level, this Yox1p-dependent inhibition of formation of Mcm1p-Fkh2p-Ndd1p complexes would result in a delay in the timing of activation of the *CLB2* cluster genes containing the Yox1p-binding site compared to those that do not, which is exactly what is seen ([Figure 4](#fig4){ref-type="fig"}; [@bib25]). Previous work has suggested that cell cycle-dependent gene expression of *YOX1* determines the timing of repression of Yox1p target promoters ([@bib25]). In this model, fluctuating Yox1p protein levels would change its availability for promoter binding and repression. Furthermore, relatively low constitutive expression of *YOX1* represses the cyclical expression of the Yox1p target gene *MCM3* ([@bib25]). Thus, the timing of Fkh2p binding would be determined by the levels of Yox1p present in the cell. In agreement with this model, we find that constitutive expression of *YOX1* inhibited Ndd1p binding to the Yox1p-regulated *SPO12* promoter ([Figure 7](#fig7){ref-type="fig"}D). However, it is also possible that additional mechanisms contribute to the regulation of Yox1p/Fkh2p competition for Mcm1p binding. For example, Yox1p is phosphorylated by cyclin-Cdk complexes ([@bib32]), and it is possible that this triggers changes in promoter occupancy and/or the proteolytic degradation and turnover of Yox1p.

Although we have established the mechanism underlying the timing of expression of a subset of *CLB2* cluster genes in the cell cycle by Yox1p, it remains unclear how Yox1p regulates the timing of expression of ECB-controlled genes. No other common juxtaposed binding motifs are obvious in the promoter regions of ECB genes, and no other binding partners for Mcm1p that regulate ECB genes have been identified. However, it is tempting to speculate that the mechanism of action is similar to the regulation of Mcm1p-Fkh2p and involves the displacement of an as yet unidentified coactivator that competes with Yox1p for binding to the surface of the Mcm1p MADS box DNA-binding domain ([Figure 7](#fig7){ref-type="fig"}F). Notwithstanding this possibility, in both scenarios, Yox1p might also actively repress transcription through the recruitment of corepressor proteins that act, for example, on the local chromatin environment. In addition to its activator role via Ndd1p, Fkh2p also has a repressive role and recruits the Rpd3 corepressor to the *CLB2* promoter at early points in the cell cycle ([@bib33; @bib34]). However, Yox1p is unlikely to influence this activity, as the point of Yox1p function is later in the cycle during M phase.

It is unclear why such an elaborate system for repression is utilized by Yox1p, rather than a more typically found simple steric hindrance model whereby the activator and repressor proteins compete for the same site on DNA. However, DNA binding sequence constraints probably dictate that this is not possible, as the recognition motifs for Fkh2p and Yox1p are quite different. Thus, by creating a system whereby promoter recruitment is dependent on cooperative interactions with a common binding partner, transcription factors from heterologous families are able to compete for promoter occupancy. Furthermore, by invoking a third protein (in this case Mcm1p), the repressive activity of Yox1p on Fkh2p function can be made more specific and restricted to a subset of target genes on which Mcm1p is also present and leave other genes on which Fkh2p acts independently from Mcm1p ([@bib11]) unaffected.

As MADS box, forkhead, and homeodomain proteins are also found in higher eukaryotes, some aspects of the combinatorial regulation mechanisms documented here are likely to be conserved. For example, the MADS box protein SRF interacts with the forkhead proteins FOXK1 ([@bib8]) and FOXO4 ([@bib19]) and the homeodomain proteins Phox1 ([@bib9]) and Nkx-2.5 ([@bib4]). In these examples, interactions with forkhead proteins are repressive, whereas the homeodomain proteins work in a positive manner. However, the direct interplay involving interactions between these proteins has not been investigated. In a more general context, the phenomenon of sequence-specific repressor and activator proteins antagonizing each other through competing for the same protein surface on a common DNA-bound transcription factor is likely to be more widespread in timing mechanisms in other transcriptional control networks. Thus, these studies may have important implications for understanding the mechanisms by which gene expression determines the precise timing of events in cellular processes, in addition to cell proliferation, such as development.

Experimental Procedures {#sec4}
=======================

Plasmid Construction and Mutagenesis {#sec4.1}
------------------------------------

See the [Supplemental Information](#app2){ref-type="sec"} for details of plasmids used.

Protein Production, Pull-Down Assays, and Western Blotting {#sec4.2}
----------------------------------------------------------

Wild-type and truncated derivatives of Yox1p and Fkh2p were produced by coupled in vitro transcription and translation (using rabbit reticulocyte lysates, Promega) and subsequently analyzed and quantified by phosphorimaging.

His-tagged Mcm1p(1--98), Yox1p, and Fkh2p derivatives were expressed in *Escherichia coli* BL21(DE3) and purified using nickel-NTA-agarose resin (QIAGEN) according to standard procedures. MBP-Mcm1p(1--96) was prepared by maltose affinity chromatography according to standard procedures. For the experiments in [Figure S4](#app2){ref-type="sec"}B, the Mcm1p moiety was released from the fusion protein while still attached to the beads by cleavage with factor Xa.

Protein concentrations were estimated compared to BSA standards. For titration experiments, a 9-, 10-, or 25-fold concentration range was used, with typical amounts of protein ranging from ∼50 to 500 ng. When two different proteins were directly compared, protein levels were normalized by comparison on the same gel.

MBP pull-down assays with in vitro-translated and recombinant proteins were carried out as described previously for GST pull-down assays ([@bib27]). Where indicated, ethidium bromide (100 μg/ml) was added to the MBP-fusion protein immobilized on the beads prior to the addition of Yox1p proteins and was included in all wash buffers.

To detect epitope-tagged derivatives by western analysis, anti-Flag (Sigma) and anti-myc (9E10; Santa Cruz) antibodies and Supersignal west dura substrate (Pierce) were used.

Gel Retardation and Immobilized Template Assays {#sec4.3}
-----------------------------------------------

Gel retardation and immobilized template binding assays were performed as described previously ([@bib2]) using the binding sites as detailed in the [Supplemental Information](#app2){ref-type="sec"}. Complexes containing Flag-tagged Yox1p derivatives were detected by including, 2.5 μg of anti-Flag antibody (Sigma) in the binding reaction. His-tagged Mcm1p(1--98) was used in all gel retardation experiments apart from those in [Figure S4](#app2){ref-type="sec"}B in which Mcm1p(1--96) cleaved from MBP-Mcm1p(1--96) derivatives was used.

Immobilized template binding assays were performed in the same buffers as used in gel retardation assays. 14 ng of biotin-labeled DNA-binding sites were incubated with 7 μl magnetic streptavidin beads (Dynal) for 15 min with gentle shaking. The beads were subsequently washed in 100 μl binding buffer, and recombinant Mcm1p(1--98) was then added and allowed to bind for 15 min with gentle shaking. The beads were washed, and then ^35^S-labeled in vitro-translated Yox1p was added and allowed to bind for 1 hr. After washing the beads twice in binding buffer, the proteins were eluted on ice for 15 min in elution buffer (1 × PBS, 1 M NaCl) and then analyzed by 12% SDS PAGE followed by fixing, drying, and visualization by phosphorimaging.

Yeast Growth, RNA Analysis, and Chromatin Immunoprecipitations {#sec4.4}
--------------------------------------------------------------

Details of yeast strains are provided in the [Supplemental Information](#app2){ref-type="sec"}.

Yeast cells were grown, *GAL1*-promoter-driven constructs were induced, and transformations were performed as described previously ([@bib7]). Yeast cultures were synchronized in G1 phase by treatment with α-factor (5 μg/ml) for 3 hr. DNA content analyses were performed using propidium iodide-stained cells as described previously ([@bib6]).

RNA extraction and real-time RT-PCR analysis were carried out as described previously ([@bib6]) using the following primer pairs: ADS1444/1445 (*CLN2*), ADS1436/1437 (*CLB2*), ADS1704/1705 (*SPO12*), ADS1926/1927 (*CDC20*), ADS1708/1709 (*MCM3*), and ADS1439/1440 (*ACT1*). Details are available on request. All data were normalized to *ACT1* levels in the same cells.

Details of chromatin immunoprecipitation (ChIP) and re-ChIP assays are provided in the [Supplemental Information](#app2){ref-type="sec"}.

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures and Six Figures
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![Yox1p Forms a Complex with Mcm1p on the *SPO12* Promoter In Vitro\
(A) Schematic representation of the *SPO12* promoter illustrating the relative positions and sequences of the Yox1p-, Mcm1p-, and Fkh2p-binding sites within the fragments used for DNA binding studies.\
(B) Immobilized template binding assay of full-length in vitro-translated Yox1p binding to the *SPO12* promoter sequence in the presence or absence of recombinant Mcm1p(1--98). Control reactions contained streptavidin beads but no biotinylated oligonucleotides. Ten percent input is shown.\
(C) Schematic illustration of full-length and truncated Yox1p proteins, illustrating the position of the homeodomain (HD).\
(D and E) Gel retardation analysis of recombinant Flag-tagged Yox1p(151--274) binding to the *SPO12* site in the presence or absence of (D) recombinant Mcm1p or (E) Fkh2p(312--458). Where indicated, Flag antibody was added.\
(F) Gel retardation analysis of the indicated in vitro-translated Yox1p proteins binding to a *SPO12* promoter fragment in the presence or absence of recombinant Mcm1p(1--98). The bands corresponding to Mcm1p alone (black arrow) and Yox1p-Mcm1p complexes (white arrows) are indicated.\
(G) MBP pull-down assays of the indicated recombinant Flag-tagged Yox1p derivatives with MBP-Mcm1p(1--96). Yox1p proteins were detected by western analysis with anti-Flag antibody. Input lanes contain 10% total input protein. See also [Figure S1](#app2){ref-type="sec"}.](gr1){#fig1}

![The Yox1p-Binding Site Is Required for Ternary Complex Formation\
(A) Schematic representation of the wild-type and mutant *SPO12* promoter. The cross indicates that the Yox1p-binding site has been mutated, and the sequence of the mutated site is indicated (mutated bases underlined).\
(B) Gel retardation analysis of in vitro-translated Yox1p(151--274) and Fkh2p(1--458) binding to the wild-type (WT) and mutant (mut) *SPO12* promoter in the presence or absence of recombinant Mcm1p(1--98).\
(C) Gel retardation analysis of recombinant Yox1p(151--274) binding to the wild-type (WT) and indicated spacer mutant versions of the *SPO12* promoter (shown diagrammatically above the figure; additional nucleotides are underlined) in the presence or absence of recombinant Mcm1p(1--98). The bands corresponding to Mcm1p alone (black arrow), Mcm1p-Yox1p complexes (white arrow), and Mcm1p-Fkh2p complexes (gray arrow) are indicated.](gr2){#fig2}

![Identification of Amino Acids in Yox1p Critical for Interaction with Mcm1p\
(A) Schematic illustration of Yox1p(151--274) highlighting the sequence N terminal to the homeodomain (HD). Mutated versions of Yox1p(151--274) are indicated.\
(B) MBP pull-down assays of the indicated in vitro-translated Yox1p(151--274) derivatives with MBP-Mcm1p(1--96).\
(C) Gel retardation analysis of the indicated in vitro-translated Yox1p proteins binding to the *SPO12* promoter fragment in the presence (lanes 6--10) or absence (lanes 1--5) of recombinant Mcm1p(1--98). The bands corresponding to Mcm1p alone (black arrow), Yox1p-Mcm1p complexes (white arrow), and Yox1p alone (gray arrow) are indicated. See also [Figure S2](#app2){ref-type="sec"}.](gr3){#fig3}

![Mutant Yox1p Proteins Are Defective in Promoter Binding and Transcriptional Repression\
(A) Western analysis of Yox1p expression in logarithmically growing *yox1*Δ*yhp1*Δ cells containing the YCplac-based plasmids pAS2563 and pAS2568 encoding the wild-type (WT) and F155A mutant myc-tagged Yox1p derivatives, respectively. The loading control is tubulin (bottom).\
(B) Real-time RT-PCR analysis of the indicated genes in *yox1*Δ*yhp1*Δ cells containing plasmids encoding either wild-type (WT-pAS2563) (black lines) or F155A (pAS2568) (gray lines) myc-tagged Yox1p derivatives, following release from α factor block at the indicated times. Data are normalized to *ACT1* levels.\
(C) ChIP analysis of myc-tagged Yox1p derivatives binding to the indicated gene promoters in *yox1*Δ*yhp1*Δ cells containing plasmids expressing either wild-type (WT) (white bars) or F155A (black bars) Yox1p derivatives (pAS2563 or pAS2568), following release from α factor block at the indicated times. Data are shown relative to the background binding to each gene promoter in control cells harboring untagged wild-type Yox1p (control, gray bar) (taken as 1) and are the average (± SEM) of two independent experiments performed in duplicate. See also [Figure S3](#app2){ref-type="sec"}.](gr4){#fig4}

![Yox1p and Fkh2p Binding to Mcm1p Are Mutually Exclusive\
(A) Schematic illustration of full-length and truncated Yox1p proteins.\
(B--D) Gel retardation analyses using the *SPO12* promoter fragment and (B) in vitro-translated Fkh2p(1--862) in the presence of recombinant Mcm1p(1--96) and increasing amounts of recombinant Yox1p proteins (1, 5, and 10 molar equivalents; indicated by a triangle above the lanes), (C) in vitro-translated Yox1p(151--274) in the presence of recombinant Mcm1p(1--96) and increasing amounts of in vitro-translated Fkh2p(1--862) proteins (1, 2, and 4 molar equivalents; indicated by a triangle above the lanes), or (D) the indicated combinations of recombinant versions of Mcm1p(1--96), Fkh2p(325--458), and increasing amounts of Yox1p(151--274) or Yox1p(176--274) proteins (1 and 2.5 molar equivalents; indicated by a triangle above each set of lanes; lanes 6 and 9 contain the same quantity as lanes 5 and 8). The bands corresponding to Mcm1p and Fkh2p alone (black arrows), binary Yox1p-Mcm1p or Fkh2p-Mcm1p complexes (gray arrows), or ternary Mcm1p-Fkh2p-Yox1p complexes (white arrow) are indicated. Complexes containing Yox1p alone are indicated by \#. \^, a higher-order complex. ^∗^, a nonspecific band arising from the rabbit reticulocyte lysate. See also [Figure S4](#app2){ref-type="sec"}.](gr5){#fig5}

![Yox1p Determinants for Competition with Fkh2p for Mcm1p Binding\
(A and B) Gel retardation analysis of in vitro-translated Fkh2p(1--862) binding to the wild-type (WT) and Yox1p site mutant (mut) *SPO12* promoter fragments in the presence of recombinant Mcm1p(1--98) and increasing amounts of the indicated recombinant Yox1p(151--274) proteins (1, 5, and 25 molar equivalents in A and 1, 5, and 10 molar equivalents in B; indicated by a triangle above each set of lanes). The bands corresponding to Mcm1p alone (black arrows), Yox1p-Mcm1p complexes (white arrows), and Fkh2p-Mcm1p complexes (gray arrows) are indicated. Complexes containing Mcm1p and two Yox1p molecules are indicated by \#. ^∗^, a nonspecific band arising from the rabbit reticulocyte lysate. See also [Figure S5](#app2){ref-type="sec"}.](gr6){#fig6}

![Yox1p Displaces Fkh2p from Promoters In Vivo\
(A) Reporter gene assay of *SPO12* promoter activity in cells (AP18) containing either integrated pAS2000 (wild-type \[WT\] *SPO12* promoter) or pAS2001 (mutant \[mut\] *SPO12* promoter). Data are shown relative to the activity of the wild-type *SPO12* promoter (taken as 1) and are the average (± SEM) of five independent experiments.\
(B--D) ChIP assays of occupancy of either the *CLB2* promoter in its normal endogenous context or the *SPO12* promoter in the *SPO12-LACZ* fusion (B and C) or the *SPO12* promoter in its normal endogenous context (D). ChIP was performed using either anti-Myc (to detect Myc-tagged Fkh2p) or anti-Pk (to detect Pk-tagged Ndd1p) antibodies and extracts isolated from logarithmically growing AP16 (B) or AP180 (C) cells containing either integrated pAS2000 (wild-type \[WT\] *SPO12* promoter) or pAS2001 (mutant \[mut\] *SPO12* promoter), or in (D), AP180 cells containing empty vector (−) or plasmids expressing either *GAL1* promoter-driven wild-type (WT-pAS2573) or F155A (pAS2574) Yox1p derivatives. In (D), cells were grown in galactose-containing media for 4 hr before sample collection. Data are shown relative to the background binding to the *CLB2* or *SPO12* promoters in control cells (W303-1a) harboring untagged wild-type Fkh2p (B and C) or Ndd1p (D, control) (white bars) (taken as 1) and are the average (± SEM) of at least two independent experiments.\
(E) Re-ChIP analysis of Mcm1p, Pk-tagged Yox1p, and Myc-tagged Fkh2p binding to the indicated promoters following a first-round ChIP with either Pk (for Yox1p) or Myc (for Fkh2p) antibodies. Data are average of two independent experiments.\
(F) Model of how Yox1p represses cell cycle-dependent transcription. In the case of a subset of *CLB2* cluster genes, Yox1p binding causes the displacement of the activator protein Fkh2p (top). On genes expressed at the M/G1 phase border (bottom), Fkh2p is not present at the promoter, and Yox1p might act through displacement of an unknown (co-)activator (indicated as X) or through direct repressive effects. Potential protein-DNA interactions are indicated by a dotted arrow. See also [Figure S6](#app2){ref-type="sec"}.](gr7){#fig7}
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